Novavax (NVAX) said Wednesday it has agreed to sell its manufacturing facility in Bohumil, Czech Republic, to Novo Nordisk (NVO) for $200 million.
The asset sale includes a 150,000-square-foot recombinant protein manufacturing facility with support buildings.
The consideration for the deal consists of a $190 million cash payment, and a $10 million additional payment in 2025.
The company also expects the deal to reduce its annual operating costs by about $80 million.
The deal is anticipated to close by Dec. 30.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。